A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Copanlisib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Colon cancer; Endometrial cancer; Gallbladder cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Salivary gland cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Biomarker
Acronyms BaCoN

06 Feb 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
06 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
02 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com